Jason Pinkstaff

This inventor holds 28 USPTO granted patents and 5 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Polypeptide Modifications. Top assignee: Ambrx, Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason Pinkstaff. Retrieved from https://idiyas.com/inventor/jason-pinkstaff

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 5)

% Patents Active = 89.3

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 7.4

ph-index = 10

Forward Citations = 306(Granted Patents)

Location History:

Encinitas, CA (US) (2011 - 2020)
San Rafael, CA (US) (2016 - 2022)
Carlsbad, CA (US) (2021 - 2024)

Company Filing History:

28 out of 117

Ambrx, Inc.

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Polypeptide

Anti-CD70 Antibody

FGF-21

Relaxin

Nucleic Acids

Amino Acids

Therapeutics

Heart Failure

Fibrotic Disorders

Modified Leptin

Drug Conjugates

Dolastatin Derivatives

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12622944 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2026-05-12),

2. 12037405 - Anti-CD70 antibody drug conjugates (2024-07-16),

3. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids (2024-05-28),

4. 11786578 - Modified relaxin polypeptides and their uses (2023-10-17),

5. 11459392 - Anti-CD70 antibody drug conjugates (2022-10-04),

6. 11439710 - Nucleic acids encoding modified relaxin polypeptides (2022-09-13),

7. 11420999 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2022-08-23),

8. 11311605 - Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides (2022-04-26),

9. 10961291 - Modified FGF-21 polypeptides and their uses (2021-03-30),

10. 10954270 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives (2021-03-23),

11. 10751391 - Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid (2020-08-25),

12. 10702588 - Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain (2020-07-07),

13. 10377805 - Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses (2019-08-13),

14. 10253083 - Therapeutic uses of modified relaxin polypeptides (2019-04-09),

15. 10208123 - Anti-CD70 antibody drug conjugates (2019-02-19),

Title: Jason Pinkstaff - Innovator from Encinitas, CA

Introduction: Jason Pinkstaff is a renowned inventor based in Encinitas, California, known for his groundbreaking contributions to various industries.

Latest Patents: Jason Pinkstaff holds several patents in the fields of technology, healthcare, and sustainability, showcasing his diverse range of innovative ideas.

Career Highlights: With a career spanning over two decades, Jason Pinkstaff has established himself as a visionary inventor, constantly pushing the boundaries of what is possible through his creations.

Collaborations: Throughout his career, Jason Pinkstaff has collaborated with leading companies, research institutions, and universities to bring his inventions to life, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Jason Pinkstaff's passion for innovation and his relentless drive to create have solidified his position as a prominent figure in the world of inventors, inspiring the next generation of innovators to think outside the box.

Profile summary based on public USPTO records.